{
  "first_published_at": "2008-01-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084707", 
  "title": "Desmomelt (desmopressin): call for Yellow Card reporting", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\", \"haematology\", \"urology-nephrology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\", \"Haematology\", \"Urology and nephrology\"]}", 
  "_document_number": 305, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/Yellowcard_icon.png", 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism", 
    "haematology", 
    "urology-nephrology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Desmomelt (desmopressin): call for Yellow Card reporting</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Healthcare professionals are encouraged to report all suspected adverse reactions to melt formulations of desmopressin<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Desmopressin is a synthetic analogue of vasopressin. It is indicated for: treatment of primary nocturnal enuresis (PNE); nocturia associated with multiple sclerosis when other treatments have failed; diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus; establishment of renal concentration capacity; to increase Factor VIII:C and Factor VIII:Ag in patients with mild to moderate haemophilia or von Willebrand&rsquo;s disease who are undergoing surgery or after trauma; and to test for fibrinolytic response.</p><p>Desmopressin is available in nasal, oral (tablet or melt), and injection formulations. The PNE indication has been removed from all desmopressin nasal spray products because of an increased risk of hyponatraemia compared with the oral formulation (which remains available for treatment of PNE, along with the melt formulation).</p><p>Healthcare professionals should remain vigilant for signs and symptoms of hyponatraemia associated with use of desmopressin, particularly the melt formulation. These may include (in mild cases): anorexia, headache, nausea, or vomiting; or (in more severe cases) muscle cramps and weakness, confusion, convulsions, or coma.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Reminder for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Nasal formulations of desmopressin should not be used for treatment of PNE</li>\r\n\t\t\t\t<li>Healthcare professionals and patients should follow closely the advice on fluid intake in the Summary of Product Characteristics and Patient Information Leaflet to avoid hyponatraemia</li>\r\n\t\t\t\t<li>Healthcare professionals are encouraged to report all suspected adverse reactions to melt formulations of desmopressin</li>\r\n\t\t\t</ul></div><p>For further information&nbsp;see desmopressin nasal spray and removal of PNE indication: <a href=\"ssLINK/CON079167\" target=\"_blank\">Drug Safety Update Sept 2007; Vol 1, Issue 2: 7</a></p><p><a href=\"http://www.medicines.org.uk/EMC/searchresults.aspx?term=desmopressin&searchtype=QuickSearch\" target=\"_blank\">Desmopressin product information</a></p><p>Report suspected adverse reactions to a medicine or vaccine by completing a <a href=\"http://yellowcard.mhra.gov.uk/\" target=\"_blank\">Yellow Card</a></p><p>&nbsp;</p><p><font class=\"normal\"><em>Article citation: Drug Safety Update Jan 2008; Vol 1, Issue 6: 6</em></font></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Desmopressin is a synthetic analogue of vasopressin. It is indicated for: treatment of primary nocturnal enuresis (PNE); nocturia associated with multiple sclerosis when other treatments have failed; diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus; establishment of renal concentration capacity; to increase Factor VIII:C and Factor VIII:Ag in patients with mild to moderate haemophilia or von Willebrand&#8217;s disease who are undergoing surgery or after trauma; and to test for fibrinolytic response.</p><p>Desmopressin is available in nasal, oral (tablet or melt), and injection formulations. The PNE indication has been removed from all desmopressin nasal spray products because of an increased risk of hyponatraemia compared with the oral formulation (which remains available for treatment of PNE, along with the melt formulation).</p><p>Healthcare professionals should remain vigilant for signs and symptoms of hyponatraemia associated with use of desmopressin, particularly the melt formulation. These may include (in mild cases): anorexia, headache, nausea, or vomiting; or (in more severe cases) muscle cramps and weakness, confusion, convulsions, or coma.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Reminder for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Nasal formulations of desmopressin should not be used for treatment of PNE</li>\r\n\t\t\t\t<li>Healthcare professionals and patients should follow closely the advice on fluid intake in the Summary of Product Characteristics and Patient Information Leaflet to avoid hyponatraemia</li>\r\n\t\t\t\t<li>Healthcare professionals are encouraged to report all suspected adverse reactions to melt formulations of desmopressin</li>\r\n\t\t\t</ul></div><p>For further information&#160;see desmopressin nasal spray and removal of PNE indication: <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON079167\" target=\"_blank\">Drug Safety Update Sept 2007; Vol 1, Issue 2: 7</a></p><p><a href=\"http://www.medicines.org.uk/EMC/searchresults.aspx?term=desmopressin&amp;searchtype=QuickSearch\" target=\"_blank\">Desmopressin product information</a></p><p>Report suspected adverse reactions to a medicine or vaccine by completing a <a href=\"http://yellowcard.mhra.gov.uk/\" target=\"_blank\">Yellow Card</a></p><p>&#160;</p><p><font class=\"normal\"><em>Article citation: Drug Safety Update Jan 2008; Vol 1, Issue 6: 6</em></font></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-01-01", 
  "date_last_modified": "2010-08-27", 
  "_assets": [], 
  "_item_id": 305, 
  "summary": "Healthcare professionals are encouraged to report all suspected adverse reactions to melt formulations of desmopressin", 
  "body": "Article date: January 2008\n\nDesmopressin is a synthetic analogue of vasopressin. It is indicated for: treatment of primary nocturnal enuresis (PNE); nocturia associated with multiple sclerosis when other treatments have failed; diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus; establishment of renal concentration capacity; to increase Factor VIII:C and Factor VIII:Ag in patients with mild to moderate haemophilia or von Willebrand’s disease who are undergoing surgery or after trauma; and to test for fibrinolytic response.\n\nDesmopressin is available in nasal, oral (tablet or melt), and injection formulations. The PNE indication has been removed from all desmopressin nasal spray products because of an increased risk of hyponatraemia compared with the oral formulation (which remains available for treatment of PNE, along with the melt formulation).\n\nHealthcare professionals should remain vigilant for signs and symptoms of hyponatraemia associated with use of desmopressin, particularly the melt formulation. These may include (in mild cases): anorexia, headache, nausea, or vomiting; or (in more severe cases) muscle cramps and weakness, confusion, convulsions, or coma.\n\nReminder for healthcare professionals:  \n  \n  * Nasal formulations of desmopressin should not be used for treatment of PNE  \n  * Healthcare professionals and patients should follow closely the advice on fluid intake in the Summary of Product Characteristics and Patient Information Leaflet to avoid hyponatraemia  \n  * Healthcare professionals are encouraged to report all suspected adverse reactions to melt formulations of desmopressin  \n  \nFor further information see desmopressin nasal spray and removal of PNE indication: [Drug Safety Update Sept 2007; Vol 1, Issue 2: 7](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON079167)\n\n[Desmopressin product information](http://www.medicines.org.uk/EMC/searchresults.aspx?term=desmopressin&searchtype=QuickSearch)\n\nReport suspected adverse reactions to a medicine or vaccine by completing a [Yellow Card](http://yellowcard.mhra.gov.uk/)\n\n \n\nArticle citation: Drug Safety Update Jan 2008; Vol 1, Issue 6: 6\n"
}